ETF Managers Group, LLC Aligos Therapeutics, Inc. Transaction History

ETF Managers Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.04 - $2.14 $584 - $1,202	562 Added 4.35%	13,489 $17,000
Q1 2022 May 13, 2022	BUY	$2.08 - $12.2 $97 - $573	47 Added 0.36%	12,927 $27,000
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $30,743 - $47,373	-2,678 Reduced 17.21%	12,880 $154,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $62,709 - $76,266	4,304 Added 38.24%	15,558 $236,000
Q2 2021 Aug 16, 2021	SELL	$20.3 - $33.6 $8,546 - $14,145	-421 Reduced 3.61%	11,254 $238,000
Q1 2021 May 17, 2021	SELL	$19.1 - $34.94 $131,121 - $239,863	-6,865 Reduced 37.03%	11,675 $244,000
Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $244,728 - $606,999	18,540 New	18,540 $482,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

Stay updated on ETF Managers Group, LLC with notifications on news.